Pancreatic Cancer Research

ResearcherUniversity of UtahNo recent work listed

Martin McMahon

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-2812-1042; OpenAlex author ID A5003652463; NIH RePORTER profile ID 6483196. Sources: OpenAlex.

Their work

Papers
3 (first author 0, last author 2)
Trials
0
Grants
1
Labs led
1
Collaborators
7
Papers, trials and grants by year

2011: 1 grant · 2012: 2 papers · 2013: none · 2014: none · 2015: none · 2016: none · 2017: none · 2018: none · 2019: none · 2020: none · 2021: none · 2022: none · 2023: 1 paper

Papers 3

  1. MYC-mediated resistance to trametinib and HCQ in PDAC is overcome by CDK4/6 and lysosomal inhibition. Co-author DOI 10.1084/jem.20221524↗
  2. Analysis of mRNA profiles after MEK1/2 inhibition in human pancreatic cancer cell lines reveals pathways involved in drug sensitivity. Last author DOI 10.1158/1541-7786.mcr-12-0188↗
  3. A central role for RAF→MEK→ERK signaling in the genesis of pancreatic ductal adenocarcinoma. Last author DOI 10.1158/2159-8290.cd-11-0347↗

Grants 1

  1. PANCREAS CANCER PROGRAM P30CA082103↗

Closest collaborators

The 7 strongest of 7 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Mark R. Silvis · 1 shared paper, 2023 · strength 0.18
  2. Kajsa E. Affolter · 1 shared paper, 2023 · strength 0.18
  3. Conan Kinsey · 1 shared paper, 2023 · strength 0.18
  4. Stephan Gysin · 1 shared paper, 2012 · strength 0.05
  5. Joe W. Gray · 1 shared paper, 2012 · strength 0.03
  6. Paul T. Spellman · 1 shared paper, 2012 · strength 0.03
  7. Eric Andrew Collisson · 1 shared paper, 2012 · strength 0.03

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.